Immunologic Research

, Volume 61, Issue 1–2, pp 90–96 | Cite as

The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems

  • Paolo Pellegrino
  • Valentina Perrone
  • Marco Pozzi
  • Carla Carnovale
  • Cristiana Perrotta
  • Emilio Clementi
  • Sonia Radice
CUTTING EDGE IN AUTOIMMUNITY

Abstract

The term “ASIA—Autoimmune/inflammatory Syndrome Induced by Adjuvants” describes an umbrella of clinical conditions sharing similar signs or symptoms, including post-vaccination phenomena. No information is available on the epidemiology of the ASIA syndrome, especially following HPV vaccination. We carried out an analysis of the VAERS database to retrieve all cases of suspected ASIA syndrome according to the Shoenfeld and Agmon-Levin’s guideline for the diagnosis. After causality assessment and case validation, 2,207 cases were considered probably or possibly related to vaccination. These represent the largest ASIA cohort ever reported and allowed us to estimate epidemiological and clinical characteristic of this syndrome. The commonest clinical manifestation observed were pyrexia (58 %), myalgia (27 %) and arthralgia or arthritis (19 %), and the estimated reporting rate was of 3.6 cases per 100,000 doses of HPV vaccine distributed (95 % CI 3.4–3.7). This study presents the first systematic estimation of ASIA incidence and expands the knowledge on this pathology. Further analyses are needed to identify genetic and non-genetic risk factors for ASIA syndrome.

Keywords

Vaccine ASIA Adjuvants Post-vaccination HPV 

References

  1. 1.
    Shoenfeld Y, Agmon-Levin N. ‘ASIA’: autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8. doi:10.1016/j.jaut.2010.07.003.PubMedCrossRefGoogle Scholar
  2. 2.
    Meroni PL. Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome? J Autoimmun. 2011;36(1):1–3. doi:10.1016/j.jaut.2010.10.004.PubMedCrossRefGoogle Scholar
  3. 3.
    Carvalho JF, Barros SM. ASIA or Shoenfeld’s syndrome: a novel autoimmune syndrome? Rev Bras Reumatol. 2010;50(5):487–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Carvalho JF, Barros SM, Branco JC, Fonseca JE. Asia or Shoenfeld’s syndrome: highlighting different perspectives for diffuse chronic pain. Acta Reumatol Port. 2011;36(1):10–2.PubMedGoogle Scholar
  5. 5.
    Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus. 2012;21(2):118–20. doi:10.1177/0961203311429316.PubMedCrossRefGoogle Scholar
  6. 6.
    Perricone C, Shoenfeld Y. Hepatitis B vaccination and undifferentiated connective tissue disease: another brick in the wall of the autoimmune/inflammatory syndrome induced by adjuvants (Asia). J Clin Rheumatol. 2013;19(5):231–3. doi:10.1097/RHU.0b013e31829d56f1.PubMedCrossRefGoogle Scholar
  7. 7.
    Toubi E. ASIA-autoimmune syndromes induced by adjuvants: rare, but worth considering. Isr Med Assoc J. 2012;14(2):121–4.PubMedGoogle Scholar
  8. 8.
    Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52. doi:10.1177/0961203311429318.PubMedCrossRefGoogle Scholar
  9. 9.
    Pellegrino P, Carnovale C, Perrone V, Antoniazzi S, Pozzi M, Clementi E, et al. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol. 2013;28(8):705–7. doi:10.1007/s10654-013-9830-y.PubMedCrossRefGoogle Scholar
  10. 10.
    Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13(7):736–41. doi:10.1016/j.autrev.2014.01.054.PubMedCrossRefGoogle Scholar
  11. 11.
    Perricone C, Agmon-Levin N, Valesini G, Shoenfeld Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego. Joint Bone Spine. 2012;79(1):1–3. doi:10.1016/j.jbspin.2011.10.006.PubMedCrossRefGoogle Scholar
  12. 12.
    Pellegrino P, Carnovale C, Perrone V, Antoniazzi S, Pozzi M, Clementi E, et al. Can HPV immunisation cause ADEM? Two case reports and literature review. Mult Scler. 2014;20(6):762–3. doi:10.1177/1352458513502114.PubMedCrossRefGoogle Scholar
  13. 13.
    Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Antoniazzi S, et al. Human papillomavirus vaccine in patients with systemic lupus erythematosus. Epidemiology. 2014;25(1):155–6. doi:10.1097/EDE.0000000000000033.PubMedCrossRefGoogle Scholar
  14. 14.
    Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T, et al. On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol. 2014;71(4):293–4. doi:10.1111/aji.12190.PubMedCrossRefGoogle Scholar
  15. 15.
    Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, et al. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012;30(50):7253–9. doi:10.1016/j.vaccine.2012.09.074.PubMedCrossRefGoogle Scholar
  16. 16.
    Harper DM, Irons BB, Alexander NM, Comes JC, Smith MS, Heutinck MA, et al. Quantifying the decisional satisfaction to accept or reject the Human Papillomavirus (HPV) vaccine: a preference for cervical cancer prevention. PLoS One. 2014;9(2):e88493. doi:10.1371/journal.pone.0088493.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013;208(9):1391–6. doi:10.1093/infdis/jit360.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Harper DM, Vierthaler SL. Next generation cancer protection: the bivalent HPV vaccine for females. ISRN Obstet Gynecol. 2011;2011:457204. doi:10.5402/2011/457204.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10. doi:10.1016/S1470-2045(11)70287-X.PubMedCrossRefGoogle Scholar
  20. 20.
    Pellegrino P, Carnovale C, Cattaneo D, Perrone V, Antoniazzi S, Pozzi M, et al. Pharmacovigilance knowledge in family paediatricians. A survey study in Italy. Health Policy. 2013;113(1–2):216–20. doi:10.1016/j.healthpol.2013.08.006.PubMedCrossRefGoogle Scholar
  21. 21.
    Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21(7):711–4. doi:10.1177/0961203312438115.PubMedCrossRefGoogle Scholar
  22. 22.
    Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA): animal models as a proof of concept. Curr Med Chem. 2013;20(32):4030–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1–16. doi:10.1016/j.jaut.2013.10.004.PubMedCrossRefGoogle Scholar
  24. 24.
    Soriano A, Butnaru D, Shoenfeld Y. Long-term inflammatory conditions following silicone exposure: the expanding spectrum of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Clin Exp Rheumatol. 2014;32(2):151–4.PubMedGoogle Scholar
  25. 25.
    Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Clementi E, et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. PLoS One. 2013;8(10):e77766. doi:10.1371/journal.pone.0077766.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T, et al. On the possible interaction between vaccines and drugs. Eur J Clin Pharmacol. 2014;70(3):369–71. doi:10.1007/s00228-013-1616-3.PubMedCrossRefGoogle Scholar
  27. 27.
    Pellegrino P, Clementi E, Radice S. Infections, vaccinations, drugs and interactions. Eur J Clin Pharmacol. 2014;. doi:10.1007/s00228-014-1689-7.Google Scholar
  28. 28.
    Pellegrino P, Carnovale C, Radice S, Clementi E. Influenza-like illness after yellow fever vaccination. J Clin Virol. 2014;. doi:10.1016/j.jcv.2014.03.015.PubMedGoogle Scholar
  29. 29.
    Posteraro B, Pastorino R, Di Giannantonio P, Ianuale C, Amore R, Ricciardi W, et al. The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses. Vaccine. 2014;32(15):1661–9. doi:10.1016/j.vaccine.2014.01.057.PubMedCrossRefGoogle Scholar
  30. 30.
    Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics. 2004;5(4):417–27. doi:10.1517/14622416.5.4.417.PubMedCrossRefGoogle Scholar
  31. 31.
    Pellegrino P, Falvella FS, Perrone V, Carnovale C, Brusadelli T, Pozzi M, et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J. 2014;. doi:10.1038/tpj.2014.57.PubMedGoogle Scholar
  32. 32.
    Pellegrino P, Clementi E, Capuano A, Radice S. Can vaccines interact with drug metabolism? Pharmacol Res. 2014. doi:10.1016/j.phrs.2014.09.003.
  33. 33.
    Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Radice S, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine. 2014;32(37):4730–5. doi:10.1016/j.vaccine.2014.06.068.PubMedCrossRefGoogle Scholar
  34. 34.
    Pellegrino P, Carnovale C, Borsadoli C, Danini T, Speziali A, Perrone V, et al. Two cases of hallucination in elderly patients due to a probable interaction between flu immunization and tramadol. Eur J Clin Pharmacol. 2013;69(8):1615–6. doi:10.1007/s00228-013-1517-5.PubMedCrossRefGoogle Scholar
  35. 35.
    Kennedy RB, Ovsyannikova IG, Lambert ND, Haralambieva IH, Poland GA. The personal touch: strategies toward personalized vaccines and predicting immune responses to them. Expert Rev Vaccines. 2014;13(5):657–69. doi:10.1586/14760584.2014.905744.PubMedCrossRefGoogle Scholar
  36. 36.
    Klein SL, Poland GA. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine. 2013;31(23):2599–600. doi:10.1016/j.vaccine.2013.02.070.PubMedCrossRefGoogle Scholar
  37. 37.
    Mitchell LA, Tingle AJ, MacWilliam L, Horne C, Keown P, Gaur LK, et al. HLA-DR class II associations with rubella vaccine-induced joint manifestations. J Infect Dis. 1998;177(1):5–12.PubMedCrossRefGoogle Scholar
  38. 38.
    Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T, et al. Epidemiological analysis on two decades of hospitalisations for meningitis in the United States. Eur J Clin Microbiol Infect Dis. 2014;33(9):1519–24. doi:10.1007/s10096-014-2102-2.PubMedCrossRefGoogle Scholar
  39. 39.
    Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13(3):215–24. doi:10.1016/j.autrev.2013.10.003.PubMedCrossRefGoogle Scholar
  40. 40.
    Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5(11):648–52. doi:10.1038/nrrheum.2009.196.PubMedCrossRefGoogle Scholar
  41. 41.
    Agmon-Levin N, Arango MT, Kivity S, Katzav A, Gilburd B, Blank M et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun. 2014. doi:10.1016/j.jaut.2014.06.006.

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Paolo Pellegrino
    • 1
  • Valentina Perrone
    • 1
  • Marco Pozzi
    • 2
  • Carla Carnovale
    • 1
  • Cristiana Perrotta
    • 1
  • Emilio Clementi
    • 2
    • 3
  • Sonia Radice
    • 1
  1. 1.Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital “Luigi Sacco”University of MilanMilanItaly
  2. 2.Scientific InstituteIRCCS E. MedeaBosisio PariniItaly
  3. 3.Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, Consiglio Nazionale delle Ricerche Institute of Neuroscience, University Hospital “Luigi Sacco”University of MilanMilanItaly

Personalised recommendations